Research & Innovation

Convalescent Plasma Program

Are you a patient who has recovered
from COVID-19?

Your plasma donation can help!

As someone who has recently recovered from COVID-19, you may be able to help us explore a potential new treatment for patients with serious COVID-19 infections.

Virginia Hospital Center (VHC) is a partner site for the Mayo Clinic’s investigational convalescent plasma program. Convalescent plasma refers to blood plasma collected from individuals who have recovered from COVID-19, which is then used to treat other hospitalized patients with advanced illness. This program explores the use of convalescent plasma as a potential treatment for hospitalized patients with severe or life-threatening COVID-19, or those at high risk of progression to severe or life-threatening disease.

Because you were diagnosed with COVID-19, your plasma may have antibodies that can attack the virus. Donating your plasma may help other patients recover.

In order to donate plasma, you must be:

  • Free of symptoms for 14 days and have a repeat antigen test with a negative result. You may also donate plasma if you are free of symptoms for 28 days and have a test documenting the presence of antibodies. Virginia Hospital Center is currently offering follow-up antigen testing through our drive-through COVID-19 sample collection site on Quincy Street in Arlington.
  • 17 years of age or older, weigh at least 110 pounds and be in good health.
If you are interested in being a plasma donor, please send an email to plasmadonation@virginiahospitalcenter.com, and a VHC representative will contact you with information on obtaining follow up testing and donation.

Rapid Testing

Virginia Hospital Center (VHC) is among the first hospitals in the nation to receive the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.

The ID NOW COVID-19 Emergency Use Authorization (EUA)  has been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2. For more information, click on the links below:


Medication for COVID-19 Treatment Trial

Virginia Hospital Center (VHC) has joined a national clinical trial to test a potential medication for the treatment of COVID-19. Hospitalized adult patients with a confirmed COVID-19 diagnosis and significant symptoms – including difficulty breathing, using supplemental oxygen or needing a ventilator – may be enrolled in the trial through VHC.

The trial will evaluate the safety and effectiveness of remdesivir, an antiviral drug previously tested in humans for the treatment of Ebola. Remdesivir has shown promise in animal studies as a treatment for Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) which are both caused by different types of coronavirus.

“Investigating all potential treatments for this novel coronavirus is a top priority here at VHC as we work to provide our patients with the best possible care,” said Jeffrey DiLisi, M.D., Chief Medical Officer of Virginia Hospital Center. “We are optimistic that the data collected through this valuable study may help to positively shape the outcomes for all patients diagnosed with COVID-19 going forward.”

Participants in the trial will be randomly assigned to either receive remdesivir or a placebo intravenously for up to 10 days. Trial participants and their doctors will not know whether patients are receiving the medication or a placebo. Patients will otherwise receive the current standard of care for their symptoms. VHC physicians will assess trial participants each day for changes in their condition.

Trial data from all participating hospitals and an estimated 440 patient participants will be combined and analyzed about halfway through the trial’s enrollment period to determine whether any changes to the trial are needed. The trial could be stopped if participants are not benefiting from remdesivir, or the trial could be changed to add another medication or therapy that could improve participants’ response.

The study is funded by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health. Gilead Sciences Inc., which developed remdesivir, is supplying it for the study.